her2-low status as a therapeutic target in advanced breast cancer
Published 2 years ago • 92 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:09
the exciting new field of her2-low breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
2:30
prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis
-
5:16
treatment options for her2-low breast cancer: all you need to know
-
2:05
latest news in her2-low breast cancer
-
0:46
biological behaviour of her2-low bc is dependent on hr expression
-
30:27
advances in her2-positive and her2-low breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
0:52
defining her2-low breast cancer as a clinical subtype
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
1:33
questions remaining in the field of her2-low breast cancer
-
6:51
adcs for her2 and her2-low breast cancer
-
2:09
the evolution of her2 targeting in metastatic breast breast cancer
-
11:25
podcast 293: her2-“low” breast cancer and its reponse to an antibody-drug conjugate